

# Which PrEP Regimen for Which Person: Considerations for Specific Populations

## PrEP Regimens Used in Asia

| Drug               | Formulation  |
|--------------------|--------------|
| FTC/TDF or 3TC/TDF | Oral         |
| FTC/TAF            | Oral         |
| DVR                | Vaginal ring |
| LA CAB             | Injectable   |

## Adolescents and Young Adults

**Oral PrEP:** TDF/FTC is not contraindicated for adolescents and young adults younger than 25 years old. However, owing to ongoing bone formation at these ages, consider one of the following:

- For adolescents younger than 18 years, prefer TAF/FTC over TDF/FTC
- For adolescents and adults younger than 25 years and on TDF/FTC, provide elemental calcium and vitamin D supplements

**DVR and LA CAB:** Suitable for adolescents and young adults

**Weight criteria:** Those who weigh less than 35 kg are not suitable for TDF-based PrEP or LA CAB

**Tailoring PrEP follow-up:** Adolescents and young adults face challenges that diminish their effective PrEP use. Consider tailoring follow-up to ensure effective PrEP use among this population. These strategies may include more regular follow-up visits and peer support groups.

## Trans and Gender-diverse People<sup>6</sup>


**Oral PrEP:** Transgender women taking estradiol-based gender-affirming hormones are not eligible for 2:1:1 dosing.

**LA CAB:** No interactions with gender-affirming hormones are expected.

**DVR:** No data on neovagina.

## Individuals With Renal Impairment<sup>1</sup>

### PrEP Options for Patients With Renal Dysfunction



- If eGFR  $\geq 60$  mL/min/1.73m<sup>2</sup>, all PrEP products can be used
- If eGFR 30-60 mL/min/1.73m<sup>2</sup>, avoid TDF/FTC
- If eGFR  $< 30$  mL/min/1.73m<sup>2</sup>, avoid TDF/FTC and TAF/FTC

## People Who Inject Drugs<sup>2</sup>

**All** PrEP products except DVR can be used.

## Pregnancy and Breastfeeding<sup>3</sup>

**All** PrEP products can be used.

## People Taking Hormonal Contraception<sup>4,5</sup>

**All** PrEP products can be used.  
No interactions on hormonal contraception are expected.

## People With Hepatitis B Infection<sup>7</sup>

**Oral PrEP:** Determine if indicated for hepatitis B treatment. If yes, prefer daily oral TDF/FTC or TAF/FTC. If no, both on-demand and daily dosing of oral PrEP can be used.

**LA CAB:** Safe to use for PrEP, but not effective against HBV infection. Avoid if acute hepatitis or advanced liver disease is suspected.

3TC, lamivudine; CAB, cabotegravir; DVR, dapivirine vaginal ring; eGFR, estimated glomerular filtration rate; FTC, emtricitabine; LA, long-acting; PrEP, pre-exposure prophylaxis; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate

To download this **Interactive Decision Support Tool**  
Go to: [clinicaloptions.com/2025prepforprescribersprogram](https://clinicaloptions.com/2025prepforprescribersprogram)



## References:

1. [iris.who.int/bitstream/handle/10665/378164/9789240097230-eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/378164/9789240097230-eng.pdf?sequence=1).
2. [who.int/publications/i/item/9789240097230](https://who.int/publications/i/item/9789240097230).
3. [who.int/publications/i/item/9789240097230](https://who.int/publications/i/item/9789240097230).
4. [who.int/publications/i/item/9789240097230](https://who.int/publications/i/item/9789240097230).
5. [pubmed.ncbi.nlm.nih.gov/24785951/](https://pubmed.ncbi.nlm.nih.gov/24785951/).
6. [who.int/publications/i/item/9789240097230](https://who.int/publications/i/item/9789240097230).
7. [who.int/publications/i/item/9789240097230](https://who.int/publications/i/item/9789240097230).